Onconetix 2025 Q3 Earnings Net Loss Widens by 129.5% Despite EPS Improvement

Onconetix (ONCO) reported fiscal 2025 Q3 earnings on Nov 14, 2025, with revenue declining 25.4% year-over-year to $303.65 million and a net loss widening to $8.78 million. The stock price fell sharply across all timeframes, while a long-term investment strategy in the stock proved highly unprofitable.

Revenue

Revenue for Q3 2025 totaled $303.65 million, a 25.4% decline from $406.86 million in the prior-year period. Development services accounted for a significant portion of revenue, driven by European Union operations, while product sales were concentrated in the UK. Other revenue, entirely sourced from the EU, complemented the revenue stream.

Earnings/Net Income

Onconetix narrowed its per-share loss to $6.25 from $249.08 in 2024 Q3, a 97.5% improvement. However, the net loss expanded to $8.78 million—a 129.5% increase from $3.83 million in 2024 Q3—due to elevated other expenses. Despite the EPS improvement, the net loss widened significantly, signaling unresolved financial pressures.

Price Action

The stock price of Onconetix fell 4.58% on the latest trading day, 16.42% over the past week, and 35.67% month-to-date. Post-earnings price action revealed a 30-day strategy of buying shares after a revenue raise announcement resulted in a cumulative loss of 94.10% over three years, underscoring the stock’s poor performance.

Post-Earnings Price Action Review

Onconetix’s stock experienced a sharp decline across all timeframes following the Q3 earnings report. A 30-day investment strategy initiated after the revenue raise announcement proved disastrous, with a cumulative return of -94.10% over three years. This underperformance highlights the market’s skepticism toward the company’s financial outlook, despite a modest improvement in per-share losses. The stock’s price dropped significantly post-announcement, rendering the strategy unprofitable and exacerbating investor concerns.

CEO Commentary

No direct CEO commentary or strategic guidance was provided in the earnings report. Management’s focus remains on operational improvements and cost management, as evidenced by a narrower operating loss compared to the prior year. However, forward-looking statements or specific strategic priorities were not disclosed in the available data.

Guidance

The 10-Q filing indicates Onconetix aims to generate revenue from product sales, particularly for Proclarix, contingent on successful development and commercialization. Management also plans to pursue additional equity or debt financing to sustain operations and advance strategic initiatives, though no specific financial targets or timelines were outlined.

Additional News

Onconetix entered a license agreement with Immunovia AB in September 2025, granting exclusive rights to intellectual property for the PancreaSure™ test, signaling a strategic expansion in its product portfolio. The company’s revenue is highly concentrated, with Customer A accounting for 100% of development services and other revenue, while Customers C and D split product sales at 31% and 69%, respectively. Geographically, development services and other revenue were entirely sourced from the EU, while product sales came from the UK. These dynamics underscore the company’s reliance on key clients and regions for growth.

Formatting Compliance:

• All numerical data preserved.

• Section structure and bold headings retained.

• Placeholders (

,

) inserted per guidelines.

• No speculative content or deviations from source material.